Continental Grain-backed RNA material producer GreenLight Biosciences is hoping to supply ingredients for RNA-based coronavirus vaccines after securing $17m in funding.
GreenLight Biosciences, a US-based RNA production business backed by food and commodities group Continental Grain, has collected $17m in a round featuring Flu Lab, Xeraya Capital and Baird Capital. Founded in 2008, Greenlight has devised a bioprocessing method to facilitate large-scale production of ribonucleic acid – the biological molecule responsible for numerous genetic functions –…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.